Literature DB >> 34822814

The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics.

Gargi Dixit1, Arati Prabhu2.   

Abstract

The Peroxisome proliferator-activated receptors (PPARs) are key regulators of metabolic events in our body. Owing to their implication in maintenance of homeostasis, both PPAR agonists and antagonists assume therapeutic significance. Understanding the molecular mechanisms of each of the PPAR isotypes in the healthy body and during disease is crucial to exploiting their full therapeutic potential. This article is an attempt to present a rational analysis of the multifaceted therapeutic effects and underlying mechanisms of isotype-specific PPAR agonists, dual PPAR agonists, pan PPAR agonists as well as PPAR antagonists. A holistic understanding of the mechanistic dimensions of these key metabolic regulators will guide future efforts to identify novel molecules in the realm of metabolic, inflammatory and immunotherapeutic diseases.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Diabetes; Dyslipidemia; Metabolic disorders; PPAR modulators; Peroxisome proliferator-activated receptors

Mesh:

Substances:

Year:  2021        PMID: 34822814     DOI: 10.1016/j.yexmp.2021.104723

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  2 in total

1.  In vitro activity of a panel of per- and polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays.

Authors:  Nicola Evans; Justin M Conley; Mary Cardon; Phillip Hartig; Elizabeth Medlock-Kakaley; L Earl Gray
Journal:  Toxicol Appl Pharmacol       Date:  2022-06-22       Impact factor: 4.460

Review 2.  Toward a Mechanistic Understanding of Poly- and Perfluoroalkylated Substances and Cancer.

Authors:  Raya I Boyd; Saeed Ahmad; Ratnakar Singh; Zeeshan Fazal; Gail S Prins; Zeynep Madak Erdogan; Joseph Irudayaraj; Michael J Spinella
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.